US-headquartered biotechnology company Proclara Biosciences closed a $47m series E round yesterday backed by Merieux Developpement, the strategic investment arm of healthcare technology provider Institut Mérieux.
The round, which included undisclosed exiting investors, was announced as Proclara changed its name from NeuroPhage Pharmaceuticals. It increased the company’s overall funding to more than $110m.
Proclara is developing treatments for diseases caused by protein misfolding, such as Alzheimer’s and Parkinson’s.
The series E financing will support a phase 1b clinical trial for…
